S-365598 is under clinical development by ViiV Healthcare and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase I drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how S-365598’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
S-365598 overview
S-365598 is under development for the treatment of human immunodeficiency virus (HIV) infections (AIDS). It is an ultra long-acting injection administered through oral and subcutaneous route. The therapeutic candidate is a third-generation integrase strand transfer inhibitor (INSTI).
See Also:
ViiV Healthcare overview
ViiV Healthcare (ViiV), a subsidiary of GSK plc, is a research company. It researches and develops the use of HIV medicines. The company offers nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and CCR5 antagonists for the treatment of AIDS. Its products include dolutegravir, zidovudine, fosamprenavi, maraviroc, abacavir, and nelfinavir. ViiV also offers various fellowship programs for primary care HIV specialists. The company partners with the HIV community to provide education and support services to people with AIDS. It operates in Japan, the US, the Netherlands, the UK, Australia, Portugal, China, Switzerland, Puerto Rica and Belgium. ViiV is headquartered in Brentford, the UK.
For a complete picture of S-365598’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
